Drugs Made In America Acquisition Corp. (DMAAU) EBIT (2025)
Drugs Made In America Acquisition's (DMAAU) quarterly EBIT came in at -$2.1 million in Q4 2025, down 692.36% on a QoQ basis from -$263703.0 in Q3 2025.
Drugs Made In America Acquisition Corp. (DMAAU) EBIT (2025) Analysis & Trends
Drugs Made In America Acquisition (DMAAU) has 1 years of EBIT data on file, last reported at -$2.1 million in Q4 2025.
- Quarterly EBIT changed N/A year-over-year to -$2.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$2.8 million (changed N/A YoY) and the FY2025 annual result came in at -$2.8 million, down 906.28% from the prior year.
- EBIT slipped to -$2.1 million in Q4 2025, from -$263703.0 in the prior quarter.
- In the past five years, EBIT ranged from a high of -$131919.0 in Q2 2025 to a low of -$2.1 million in Q4 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.09 Mn |
| Sep 30, 2025 | -263,703.00 |
| Jun 30, 2025 | -131,919.00 |
| Mar 31, 2025 | -330,925.00 |